Subtle%20Shapes%20Transparent_edited.png

ARCHBOW CONSULTING NEWS

  • Kevin Cast

6 Market Access Mistakes Cell and Gene Therapy Companies Make

A New Whitepaper from Archbow Consulting and Valuate Health Consultancy

Available for free download now


Free Whitepaper Available for Download Now

Despite an abundance of marketplace uncertainties during a global pandemic, the pace of activity in cell and gene therapies (CGTs) has not slowed. If anything, it has only continued to accelerate.


As these products begin to seek regulatory approval for commercial use, manufacturers are looking to the trailblazing organizations that have preceded them to market in hopes of learning from others’ mistakes.


Manufacturers are asking, “When things went wrong during the commercial launch of other CGTs, where did it go wrong, and why? How can we avoid making the same mistakes?”


In working with various CGT manufacturers, Archbow Consulting and Valuate Health Consultancy have identified previous commercialization mistakes that market access teams can proactively avoid with the right approach and preparation. The six mistakes featured here are some of the most common and likely some of the easiest to anticipate and overcome.


The 6 Market Access Mistakes Cell and Gene Therapy Companies Make whitepaper includes:

  • An overview of key mistakes that have been made in the marketplace

  • How manufacturers can avoid making the same mistakes

  • Essential timelines for each area


The whitepaper is available for free download now.


The earlier CGT manufacturers start engaging key commercial stakeholders, the greater the opportunity to ensure success by avoiding common mistakes. Good consulting partners can drive CGT commercial success by identifying, addressing, and effectively overcoming potential mistakes, so that market access teams can focus on what they do best – ensuring their therapies make it into the hands of the patients that need them most. Contact us today to engage with the CGT experts at Archbow and Valuate.


Archbow Consulting and Valuate Health Consultancy are sister companies under the Entrée Health Value and Access vertical of Omnicom Health Group. Learn more about our united organizations here.


 

Archbow Consulting helps pharmaceutical and biotech companies in the USA and Europe design, build, and optimize product distribution and patient access strategies. Archbow was founded by industry veterans to meet a need in the marketplace for consulting options that offer diverse real-world experience, are able to leverage deep connections across the industry, and can also provide actionable strategic guidance. We invite you to learn more about our team, services, and clients’ success, and connect with us via email, LinkedIn, Twitter or subscribing to this blog which you can do below.